摘要：SummaryDiabetic peripheral neuropathy (DPN) is a common diabetic complication and has yet no efficient medication. Here, we report that antispasmodic drug drofenine (Dfe) blocks Kv2.1 and ameliorates DPN-like pathology in diabetic mice. The underlying mechanisms are investigated against the DPN mice within vivoKv2.1 knockdown through adeno associated virus AAV9-Kv2.1-RNAi. Streptozotocin (STZ) induced type 1 ordb/dbtype 2 diabetic mice with DPN exhibited a high level of Kv2.1 protein in dorsal root ganglion (DRG) tissue and a suppressed neurite outgrowth in DRG neuron. Dfe promoted neurite outgrowth by inhibiting Kv2.1 channel and/or Kv2.1 mRNA and protein expression level. Moreover, it suppressed inflammation by repressing IκBα/NF-κB signaling, inhibited apoptosis by regulating Kv2.1-mediated Bcl-2 family proteins and Caspase-3 and ameliorated mitochondrial dysfunction through Kv2.1/CaMKKβ/AMPK/PGC1α pathway. Our work supports that Kv2.1 inhibition is a promisingly therapeutic strategy for DPN and highlights the potential of Dfe in treating this disease.Graphical AbstractDisplay OmittedHighlights•Antispasmodic drug drofenine (Dfe) ameliorates DPN-like pathology in diabetic mice•Dfe inhibits Kv2.1 channel and/or Kv2.1 mRNA and protein expression level•Dfe represses inflammation, apoptosis, and mitochondrial dysfunction in DPN mice•Kv2.1 inhibition is a therapeutic tactic and Dfe shows therapeutic potential for DPNHuman Metabolism; Immunology
